Denileukin diftitox

General information

Denileukin diftitox is a genetically engineered fusion protein combining the enzymatically active domains of diphtheria toxin and the full-length sequence for interleukin-2 (IL-2). It targets lymphoma cells that express the high-affinity IL-2 receptor. In vitro, the retinoid X receptor retinoid bexarotene upregulated both the p55 and p75 subunits of the IL-2 receptor and enhanced five- to ten-fold the susceptibility of T cell leukemia cells to denileukin diftitox [ ].

Organs and systems